ADMA submits RI-002 biologics license application to FDA
PI causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.
The one-year open-label, multi-center, single arm ADRESU trial is designed to evaluate the efficacy and safety of periurethral injection of autologous adipose derived regenerative cells for the treatment
According to the announcement, the interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection. The VSV-ZEBOV